According to Endpoints News, FDA officials stated that the Center for Biologics Evaluation and Research (CBER) review staff are "unanimous" that Elevidys should never return to market. The report ...

Sarepta Therapeutics (SRPT) stock drops as the company faces potential FDA-mandated studies after safety concerns over its ...

For Sarepta, the hits keep coming, with several downgrades in the past week after it was forced to temporarily take its ...

Sarepta stock plunged again Thursday on a report the FDA will require additional clinical testing to validate the safety ...

Federal criminal and civil investigations are underway against UnitedHealth Group’s market-leading Medicare business. The ...